SMAD3 (Ab-204) Antibody

What is SMAD3 (Ab-204) Antibody and what does it specifically target?

SMAD3 (Ab-204) Antibody is a rabbit polyclonal antibody that specifically recognizes SMAD3 around the phosphorylation site of serine 204 (A-G-S(p)-P-N). It is designed to detect the non-phosphorylated form of SMAD3 at this specific residue. The antibody is a crucial tool for researchers investigating TGF-β signaling pathways, as SMAD3 functions as a receptor-regulated SMAD (R-SMAD) that serves as an intracellular signal transducer and transcriptional modulator activated by TGF-beta and activin type 1 receptor kinases. When selecting this antibody for research, it's important to consider that it has been synthesized using a non-phosphopeptide derived from human SMAD3, making it suitable for detecting the native protein state prior to phosphorylation events.

What are the key technical specifications of SMAD3 (Ab-204) Antibody?

The SMAD3 (Ab-204) Antibody has several important technical specifications that researchers should consider when planning experiments:

For optimal experimental results, it's recommended to validate the antibody in your specific experimental system using appropriate positive and negative controls. The cross-reactivity across human, mouse, and rat samples makes this antibody valuable for comparative studies across these species.

How should SMAD3 (Ab-204) Antibody be stored and handled for optimal research results?

Proper storage and handling of SMAD3 (Ab-204) Antibody is critical for maintaining its activity and specificity. Upon receipt, the antibody should be stored at -20°C or -80°C to preserve its integrity. Researchers should avoid repeated freeze-thaw cycles as this can lead to protein denaturation and loss of antibody function. When working with the antibody, it should be thawed on ice and kept cold during experimental procedures to minimize degradation. For dilution purposes, researchers should use the appropriate buffer systems as recommended in specific application protocols. The antibody is provided in a diluent buffer containing phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol, which helps maintain stability. For long-term storage, aliquoting the antibody into smaller volumes before freezing is recommended to avoid repeated freeze-thaw cycles that could compromise antibody performance.

What is the biological role of SMAD3 in TGF-β signaling?

SMAD3 plays a critical role in the TGF-β signaling pathway as a receptor-regulated SMAD (R-SMAD) that functions as an intracellular signal transducer and transcriptional modulator. Upon TGF-β binding to its receptor, SMAD3 becomes phosphorylated at specific residues, which triggers its activation and subsequent complex formation with SMAD4. This SMAD3/SMAD4 complex then translocates to the nucleus where it binds to the TRE (TGF-β responsive element) in the promoter region of many genes regulated by TGF-β, thereby activating transcription.

Additionally, SMAD3 can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-β-mediated transcription. This versatility in complex formation allows SMAD3 to regulate a diverse range of cellular responses, including cell proliferation, differentiation, and apoptosis. Research has revealed that SMAD3 also has an inhibitory effect on wound healing, likely through modulation of growth and cellular migration processes. Understanding these mechanisms is crucial for researchers working on TGF-β signaling-related diseases, including fibrotic disorders and certain types of cancers.

How does phosphorylation at Ser-204 affect SMAD3 function in TGF-β signaling?

Phosphorylation of SMAD3 at Ser-204 represents a critical regulatory mechanism in the TGF-β signaling pathway. Research has identified that TGF-β induces phosphorylation at three sites in the SMAD3 linker region, including Ser-204, in addition to the two C-terminal residues. This linker region phosphorylation creates a negative feedback control mechanism that modulates TGF-β signaling intensity and duration.

Specifically, glycogen synthase kinase 3 (GSK3) has been identified as the kinase responsible for phosphorylation at Ser-204. Experimental evidence using alanine substitution at Ser-204 has demonstrated that this phosphorylation event significantly impacts SMAD3 function. The phosphorylation status at this residue affects SMAD3's nuclear accumulation, transcriptional activity, and interaction with other proteins in the signaling cascade.

When designing experiments to study the impact of Ser-204 phosphorylation, researchers should consider using site-specific mutants (such as S204A) to disrupt this phosphorylation event and assess the functional consequences on downstream signaling events. Additionally, phospho-specific antibodies can be valuable tools for monitoring the phosphorylation state of SMAD3 in response to various stimuli or experimental conditions.

What is the relationship between SMAD3 phosphorylation at Ser-204 and Ser-208?

The relationship between phosphorylation at Ser-204 and Ser-208 in SMAD3 represents a complex regulatory mechanism involving sequential phosphorylation events. Research has demonstrated that prior phosphorylation at Ser-208 is required for the subsequent phosphorylation at Ser-204 in vivo, establishing a priming mechanism for GSK3-mediated phosphorylation.

Experimental evidence supporting this relationship comes from point mutation studies where alanine substitution at Ser-208 abolished phosphorylation at Ser-204, whereas phosphorylation at Ser-208 was not affected by mutations at other residues. This hierarchical phosphorylation pattern highlights the importance of considering multiple phosphorylation events when studying SMAD3 regulation.

For researchers investigating these phosphorylation events, it's recommended to use both single and double mutants (S204A, S208A, and S204A/S208A) to fully understand the interdependence of these modifications. The double mutant (often referred to as 2SPAP) has been particularly valuable in understanding how these phosphorylation events collectively influence SMAD3 function and TGF-β signaling outcomes. When designing experiments, researchers should consider the potential for compensatory mechanisms and evaluate both direct and indirect effects of disrupting these phosphorylation sites.

How does SMAD3 deficiency contribute to aortic aneurysm formation?

SMAD3 deficiency leads to rapid aortic aneurysm formation and premature death in Smad3-/- animal models, providing critical insights into the molecular mechanisms of aneurysm-osteoarthritis syndrome caused by SMAD3 mutations in humans. The pathological process involves several key mechanisms that differ from other aneurysm models.

In Smad3-/- aortas, immunohistochemistry reveals no increase in extracellular matrix and collagen accumulation, nor loss of vascular smooth muscle cells (VSMCs). Instead, the primary pathological features include:

• Medial elastin disruption

• Adventitial inflammation

• Selective activation of matrix metalloproteases (MMPs) in inflammatory areas rather than in VSMCs

• Increased nuclear pSmad2 and pErk, indicating TGF-β receptor activation

• Impaired downstream TGF-β-activated target gene expression

• Increased VSMC proliferation due to impaired downstream TGF-β activated transcription

These findings suggest that Smad3 deficiency creates an imbalance in TGF-β signaling, where upstream signaling remains active but downstream transcriptional responses are compromised. This leads to weakened aortic walls and inflammatory responses that ultimately result in aortic dilation and rupture. Interestingly, the increase in pSmad2 and pErk in pre-aneurysmal Smad3-/- aortas indicates that aortic damage and TGF-β receptor activation precede aortic inflammation.

For researchers studying SMAD3-related aneurysms, these findings suggest that targeting immune responses, rather than broadly inhibiting TGF-β signaling, might be more beneficial as a therapeutic approach.

What methodological approaches are recommended for studying SMAD3 phosphorylation in experimental systems?

When studying SMAD3 phosphorylation, researchers should employ multiple complementary approaches to ensure robust and reliable results. A comprehensive methodological strategy includes:

• Site-directed mutagenesis: Generate single and combination alanine substitution mutants at key phosphorylation sites (e.g., S204A, S208A, S204A/S208A) to assess the functional importance of specific phosphorylation events. These mutants can be expressed using adenoviral vectors for efficient delivery to various cell types.

• Phospho-specific antibodies: Utilize antibodies that specifically recognize phosphorylated forms of SMAD3 at distinct sites. When combined with total SMAD3 antibodies, this approach enables quantification of the phosphorylation ratio under various experimental conditions.

• In vitro kinase assays: To determine which kinases can directly phosphorylate SMAD3 at specific sites, purified recombinant SMAD3 (full-length or domain-specific fragments) can be incubated with candidate kinases such as GSK3. GST-fusion proteins containing the SMAD3 linker region (e.g., GST-Smad3L containing Pro-147–Gln-222) are particularly useful for studying linker phosphorylation events.

• Functional readouts: Assess the impact of phosphorylation on SMAD3 function using:

  • Nuclear/cytoplasmic fractionation to track subcellular localization

  • Luciferase reporter assays using TGF-β-responsive promoters

  • Co-immunoprecipitation to detect protein interaction partners

  • Proliferation assays (e.g., 3H-thymidine incorporation)

• In vivo models: Validate findings in animal models using techniques such as adenoviral delivery of wild-type and mutant SMAD3 or through the study of knockout models. Echocardiographic measurements in Smad3-/- mice have been particularly valuable for understanding the role of SMAD3 in aortic aneurysm formation.

How can SMAD3 (Ab-204) Antibody be used to investigate gender differences in SMAD3-related pathologies?

Research with Smad3-/- mice has revealed pronounced gender differences in mortality rates, with male mice showing 65% mortality before 3 months of age compared to 22% mortality for female mice. This significant disparity suggests gender-specific mechanisms in SMAD3-related pathologies that warrant detailed investigation.

When using SMAD3 (Ab-204) Antibody to explore these gender differences, researchers should implement a systematic approach:

• Sex-stratified experimental design: Ensure equal representation of male and female samples in all experiments, with sufficient statistical power to detect gender-specific differences.

• Hormonal influence assessment: Investigate the potential role of sex hormones in modulating SMAD3 phosphorylation and function by:

  • Comparing SMAD3 phosphorylation patterns between males and females using the Ab-204 antibody

  • Evaluating hormone receptor co-localization with SMAD3 in tissue samples

  • Conducting hormone supplementation or depletion studies

• Tissue-specific analysis: Examine potential gender differences in SMAD3 expression and phosphorylation across multiple tissues, particularly focusing on aortic tissue given the aneurysm phenotype.

• Temporal dynamics: Track SMAD3 phosphorylation changes across development and aging in both males and females to identify critical windows where gender differences emerge.

This methodological approach using SMAD3 (Ab-204) Antibody can help uncover the molecular basis for gender disparities in SMAD3-related disorders such as aneurysm-osteoarthritis syndrome, potentially leading to sex-specific therapeutic interventions.

What are the optimal conditions for using SMAD3 (Ab-204) Antibody in Western blotting?

For optimal Western blotting results with SMAD3 (Ab-204) Antibody, researchers should follow these methodological guidelines:

• Sample preparation:

  • Extract proteins using a buffer containing phosphatase inhibitors to preserve phosphorylation states

  • Include protease inhibitors to prevent protein degradation

  • Denature samples in Laemmli buffer at 95°C for 5 minutes

• Gel electrophoresis:

  • Use 10% SDS-PAGE gels for optimal resolution of SMAD3 (approximately 48 kDa)

  • Run at 100-120V to ensure proper protein separation

• Transfer conditions:

  • Transfer to PVDF membrane at 100V for 60-90 minutes in standard transfer buffer

  • Verify transfer efficiency with Ponceau S staining

• Blocking:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • For phospho-specific detection, use 5% BSA instead of milk

• Primary antibody incubation:

  • Dilute SMAD3 (Ab-204) Antibody at 1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

• Secondary antibody:

  • Use anti-rabbit HRP-conjugated secondary antibody at 1:5000 dilution

  • Incubate for 1 hour at room temperature

• Detection:

  • Develop using enhanced chemiluminescence (ECL) reagents

  • Exposure time should be optimized based on signal strength

• Controls:

  • Include lysates from cells with known SMAD3 expression as positive controls

  • Consider using Smad3-/- cell lysates as negative controls when available

These conditions should be optimized based on specific laboratory equipment and sample types. For phosphorylation studies, researchers may need to run parallel blots with phospho-specific and total SMAD3 antibodies to accurately assess phosphorylation ratios.

How can researchers validate the specificity of SMAD3 (Ab-204) Antibody in their experimental systems?

Validating antibody specificity is crucial for generating reliable and reproducible research results. For SMAD3 (Ab-204) Antibody, researchers should implement the following comprehensive validation strategy:

• Genetic approaches:

  • Compare antibody reactivity in wild-type versus Smad3-/- samples

  • Use SMAD3 siRNA or shRNA knockdown systems to confirm specificity

  • Overexpress SMAD3 in low-expressing cell lines to verify signal increase

• Peptide competition:

  • Pre-incubate the antibody with excess immunizing peptide (the non-phosphopeptide derived from human Smad3 around Ser-204)

  • Compare results with and without peptide competition to identify specific bands

• Phosphorylation state validation:

  • Treat samples with phosphatases to remove phosphate groups

  • Compare detection before and after phosphatase treatment

  • Use paired phospho-specific antibodies to confirm distinct recognition patterns

• Cross-reactivity assessment:

  • Test reactivity against recombinant SMAD2 and other SMAD family members

  • Evaluate detection in multiple species (human, mouse, rat) as claimed

• Application-specific validation:

  • For Western blotting: Verify molecular weight and band pattern

  • For IHC: Include appropriate tissue controls and evaluate staining patterns

  • For ELISA: Establish standard curves with recombinant proteins

• Independent antibody comparison:

  • Compare results with other validated SMAD3 antibodies targeting different epitopes

  • Confirm consistency of findings across different detection methods

Thorough validation ensures that experimental results accurately reflect SMAD3 biology rather than non-specific interactions or artifacts. Researchers should document validation experiments thoroughly and include appropriate controls in all subsequent experiments.

What are the key considerations when designing experiments to study the relationship between SMAD3 and aortic aneurysm formation?

When investigating the relationship between SMAD3 and aortic aneurysm formation, researchers should consider the following methodological approaches to ensure comprehensive and clinically relevant results:

• Animal model selection:

  • Utilize Smad3-/- mice as primary models, with age and gender-matched controls

  • Consider heterozygous models (Smad3+/-) to mimic human haploinsufficiency

  • Compare with other aneurysm models (e.g., Marfan's syndrome models) to identify SMAD3-specific mechanisms

• Longitudinal monitoring:

  • Implement echocardiographic measurements of aortic dimensions at regular intervals

  • Track aortic diameter, length, and distensibility using high-resolution imaging

  • Monitor survival rates with particular attention to gender differences

• Molecular analysis:

  • Assess TGF-β signaling pathway activation using antibodies against:

    • Phosphorylated SMAD2 (pSmad2)

    • Phosphorylated ERK (pERK)

    • Downstream TGF-β target genes

  • Evaluate matrix metalloprotease (MMP) activation in different tissue compartments

  • Characterize inflammatory responses in the aortic wall

• Histological examination:

  • Analyze aortic wall structure, including elastin integrity and collagen deposition

  • Quantify vascular smooth muscle cell (VSMC) density and proliferation

  • Assess inflammatory cell infiltration in the adventitial layer

• Intervention studies:

  • Test the efficacy of immune suppression versus TGF-β pathway modulation

  • Evaluate timing of interventions (preventive versus therapeutic)

  • Consider sex-specific treatment approaches based on observed gender differences

• Clinical correlation:

  • Compare findings with human SMAD3 mutation carriers

  • Identify potential biomarkers for aneurysm progression

  • Develop predictive models for risk stratification

These considerations should guide experimental design to advance understanding of SMAD3's role in aneurysm formation and potentially identify novel therapeutic targets for patients with SMAD3 mutations.

How can SMAD3 (Ab-204) Antibody be used to investigate cross-talk between TGF-β signaling and other pathways?

SMAD3 (Ab-204) Antibody can be leveraged to explore the complex cross-talk between TGF-β signaling and other cellular pathways. This antibody's specificity for the Ser-204 region makes it particularly valuable for studying how different signaling cascades converge on SMAD3 phosphorylation. Researchers can implement the following methodological approaches:

• Stimulus-response experiments:

  • Treat cells with TGF-β in combination with activators or inhibitors of other pathways (e.g., GSK3 inhibitors, MAPK pathway modulators)

  • Use SMAD3 (Ab-204) Antibody to monitor changes in SMAD3 phosphorylation status

  • Correlate phosphorylation changes with functional outcomes such as gene expression or cell proliferation

• Multi-pathway phosphorylation analysis:

  • Perform parallel Western blots for SMAD3 and components of intersecting pathways

  • Use phospho-specific antibodies to track multiple phosphorylation events simultaneously

  • Construct temporal phosphorylation profiles to establish causality relationships

• Interaction proteomics:

  • Use SMAD3 (Ab-204) Antibody for co-immunoprecipitation experiments

  • Identify SMAD3 binding partners under different stimulation conditions

  • Validate interactions using reciprocal immunoprecipitation and proximity ligation assays

• Subcellular localization studies:

  • Apply immunofluorescence techniques with SMAD3 (Ab-204) Antibody to track SMAD3 localization

  • Analyze co-localization with components of other signaling pathways

  • Perform nuclear/cytoplasmic fractionation followed by Western blotting

This integrated approach enables researchers to map the complex interplay between TGF-β and other signaling networks, advancing our understanding of how SMAD3 functions as a central node in multiple cellular processes.

What methodological approaches can be used to study the effect of SMAD3 mutations on phosphorylation and function?

Studying the functional consequences of SMAD3 mutations requires a multi-faceted approach that combines molecular, cellular, and in vivo techniques. The SMAD3 (Ab-204) Antibody can be a valuable tool in this research context:

• Site-directed mutagenesis and expression systems:

  • Generate expression constructs for wild-type SMAD3 and disease-associated mutations

  • Create phosphorylation site mutants (S204A, S208A) and compound mutants

  • Establish stable cell lines or use adenoviral delivery systems for expression

• Phosphorylation analysis:

  • Compare phosphorylation patterns between wild-type and mutant SMAD3 using:

    • Western blotting with phospho-specific antibodies

    • Mass spectrometry-based phosphoproteomic analysis

    • Phosphorylation kinetics in response to TGF-β stimulation

• Functional assays:

  • Evaluate transcriptional activity using reporter gene assays

  • Assess protein-protein interactions through co-immunoprecipitation

  • Measure cellular responses such as proliferation, migration, and ECM production

  • Compare VSMC behavior between wild-type and mutant SMAD3

• Structural biology approaches:

  • Use X-ray crystallography or cryo-EM to determine how mutations affect SMAD3 structure

  • Perform molecular dynamics simulations to predict effects on protein conformation and interactions

• In vivo modeling:

  • Generate knock-in mouse models expressing specific SMAD3 mutations

  • Compare phenotypes with Smad3-/- mice to distinguish loss-of-function from dominant-negative effects

  • Perform tissue-specific and inducible expression of mutant SMAD3

These methodological approaches provide a comprehensive framework for understanding how SMAD3 mutations impact its phosphorylation, function, and contribution to disease pathogenesis. This knowledge can guide the development of targeted therapeutic strategies for SMAD3-related disorders.

What are the future directions for SMAD3 (Ab-204) Antibody in translational research?

SMAD3 (Ab-204) Antibody represents a valuable tool for advancing translational research in SMAD3-related pathologies. Future research directions should focus on leveraging this antibody to bridge the gap between basic science discoveries and clinical applications:

• Biomarker development: The antibody could be used to develop assays for detecting SMAD3 phosphorylation status as a potential biomarker for disease progression in aneurysm-osteoarthritis syndrome and related conditions. Longitudinal studies correlating SMAD3 phosphorylation patterns with clinical outcomes could identify predictive signatures for patient stratification.

• Personalized medicine approaches: By analyzing SMAD3 phosphorylation in patient samples using this antibody, researchers could potentially classify SMAD3 mutation carriers into distinct subgroups based on molecular profiles, enabling tailored therapeutic strategies. The gender differences observed in Smad3-/- mice suggest that sex-specific interventions might be beneficial.

• Therapeutic target validation: The antibody can help validate the efficacy of novel therapeutic interventions targeting SMAD3 phosphorylation or its downstream effects. The discovery that immune responses play a critical role in SMAD3-related aneurysms suggests that immune suppression, rather than direct TGF-β pathway modulation, might be more beneficial for patients with SMAD3 mutations.

• Drug discovery platforms: Incorporating SMAD3 (Ab-204) Antibody into high-throughput screening platforms could facilitate the identification of compounds that specifically modulate SMAD3 phosphorylation at Ser-204, potentially leading to more targeted therapies with fewer side effects.

• Integrative multi-omics approaches: Combining phosphorylation data from SMAD3 (Ab-204) Antibody with genomics, transcriptomics, and proteomics datasets could provide a more comprehensive understanding of SMAD3's role in disease pathogenesis and identify novel therapeutic targets.